Latest Breaking News On - New drug application - Page 10 : comparemela.com

BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER .

United statesIsrael generalPhilip serlinTwitterand linkedinPhilipa serlinGloria biosciencesMoran meirJohn laceyGloria bioscienceExchange commission onMedicaid servicesLifesci advisorsWashington university in stInternational society for pharmacoeconomicsOutcomes research onAmerican society of clinical oncology

Telix Submits NDA for New Prostate Cancer Imaging Agent

MELBOURNE, Australia, May 28, 2024 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submi.

United statesKyahn williamsonChristian behrenbruchMike crosbyWorldj mens healthGe healthcareCorporate communicationsTelix pharmaceuticals limitedTelix pharmaceuticalsHealth canadaTelix pharmaceuticals limited disclosure committeeDrug administrationAustralian securities exchangeAustralian therapeutic goods administrationPharmaceuticals limitedNew drug application

Insmed s stock rockets toward a 2-decade high after positive drug-trial data

Insmed s stock rockets toward a 2-decade high after positive drug-trial data
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Insmed incNew drug application

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesNeurocrine biosciencesRichard auchusDiurnal ltdEndocrine society annual meetingDrug administrationExchange commissionDiurnal groupNeurocrine biosciences incEuropean unionRegulatory agencyEuropean commissionAdult phaseStudy dataCongenital adrenal

Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday? - Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics announced the GRACE Phase 3 trial results for relacorilant in Cushing's syndrome, showing significant improvements in hypertension and hyperglycemia.

Corcept therapeuticsNew drug application